# Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease

> **NCT07281456** · PHASE2 · RECRUITING · sponsor: **National Institute of Dental and Craniofacial Research (NIDCR)** · enrollment: 60 (estimated)

## Conditions studied

- Sjogren's Syndrome

## Interventions

- **DRUG:** Tofacitinib

## Key facts

- **NCT ID:** NCT07281456
- **Lead sponsor:** National Institute of Dental and Craniofacial Research (NIDCR)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-18
- **Primary completion:** 2030-12-15
- **Final completion:** 2030-12-15
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07281456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07281456, "Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07281456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*